Record Display for the EPA National Library Catalog

RECORD NUMBER: 664 OF 786

Main Title Reregistration Eligibility Decision for Tiabendazole and Salts (Includes RED FACTS: Thiabendazole and Salts Fact Sheet).
CORP Author Environmental Protection Agency, Washington, DC. Office of Prevention, Pesticides and Toxic Substances.
Publisher Aug 2002
Year Published 2002
Report Number EPA/738/R-02/003;
Stock Number PB2004-105233
Additional Subjects Pesticides ; Triabendazole ; Salts ; Ecology ; Public health ; Toxicity ; Risk assessment ; Environmental exposure ; Risk management ; Mitigation ; Reregistration eligibility ; Dietary risks
Internet Access
Description Access URL
https://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=100046PU.PDF
Holdings
Library Call Number Additional Info Location Last
Modified
Checkout
Status
NTIS  PB2004-105233 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation 108p
Abstract
The Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) was amended in 1988 to accelerate deregistration of product with active ingredients registered prior to November 1, 1984. The amended Act calls for the development and submission of data to support the reregistration of an active ingredient, as well as a review of all submitted data by the U.S. Environmental Protection Agency (referred to as EPA or the Agency). Reregistration involves a thorough review of the scientific database underlying a pesticide's registration. The purpose of the Agency's review is to reassess the potential hazards arising from the currently registered uses of the pesticide; to determine the need for additional data on health and environmental effects; and to determine whether the pesticide meets the 'no unreasonable adverse effects' criteria of FIFRA. On August 3, 1996, the Food Quality Protection Act of 1996 (FQPA) was signed into law. This Act amends FIFRA to require tolerance reassessment of all existing tolerances. This document presents the Agency's revised human health and ecological risk assessments; its tolerance reassessment decision; and the decision on the reregistration eligibility of thiabendazole.